Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Carducci

Showing results (31-40 of 322) with videos related to

Pageof 33
Sort By:
The Journal of Urology|November 7, 2006
Recommendations for defining and treating high risk localized prostate cancerIan M Thompson, Peter R Carroll, Michael A Carducci
Investigational New Drugs|July 9, 2002
Endothelin-1 as a target for therapeutic intervention in prostate cancerE Scott Kopetz, Joel B Nelson, Michael A Carducci
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology|December 15, 2006
Acetylation and histone deacetylase inhibitors in cancerMadeleine S Q Kortenhorst, Michael A Carducci, Shabana Shabbeer
Clinical Advances in Hematology & Oncology : H&O|July 6, 2016
Challenges of conducting clinical trials of natural products to combat cancerChanning J Paller, Samuel R Denmeade, Michael A Carducci
BJU International|December 22, 2004
Docetaxel in androgen-independent prostate cancer: an updateMasood A Khan, Michael A Carducci, Alan W Partin
Cancer Letters|September 1, 2009
Novel targeted therapeutics for metastatic castration-resistant prostate cancerEmmanuel S Antonarakis, Michael A Carducci, Mario A Eisenberger
Cancer Metastasis Reviews|January 9, 2014
Bone-targeting agents in prostate cancerDaniel L Suzman, Sosipatros A Boikos, Michael A Carducci
The Journal of Urology|October 9, 2003
The evolving role of docetaxel in the management of androgen independent prostate cancerMasood A Khan, Michael A Carducci, Alan W Partin
Clinical Interventions in Aging|October 11, 2012
Management of bone metastases in refractory prostate cancer--role of denosumabChanning J Paller, Michael A Carducci, George K Philips
The Prostate|June 21, 2011
Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progressionDaniel Keizman, Peng Huang, Michael A Carducci, et al.
Pageof 33

Showing results (31-40 of 322) with videos related to

Sort By:
Pageof 33
The Journal of Urology|November 7, 2006
Recommendations for defining and treating high risk localized prostate cancerIan M Thompson, Peter R Carroll, Michael A Carducci
Investigational New Drugs|July 9, 2002
Endothelin-1 as a target for therapeutic intervention in prostate cancerE Scott Kopetz, Joel B Nelson, Michael A Carducci
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology|December 15, 2006
Acetylation and histone deacetylase inhibitors in cancerMadeleine S Q Kortenhorst, Michael A Carducci, Shabana Shabbeer
Clinical Advances in Hematology & Oncology : H&O|July 6, 2016
Challenges of conducting clinical trials of natural products to combat cancerChanning J Paller, Samuel R Denmeade, Michael A Carducci
BJU International|December 22, 2004
Docetaxel in androgen-independent prostate cancer: an updateMasood A Khan, Michael A Carducci, Alan W Partin
Cancer Letters|September 1, 2009
Novel targeted therapeutics for metastatic castration-resistant prostate cancerEmmanuel S Antonarakis, Michael A Carducci, Mario A Eisenberger
Cancer Metastasis Reviews|January 9, 2014
Bone-targeting agents in prostate cancerDaniel L Suzman, Sosipatros A Boikos, Michael A Carducci
The Journal of Urology|October 9, 2003
The evolving role of docetaxel in the management of androgen independent prostate cancerMasood A Khan, Michael A Carducci, Alan W Partin
Clinical Interventions in Aging|October 11, 2012
Management of bone metastases in refractory prostate cancer--role of denosumabChanning J Paller, Michael A Carducci, George K Philips
The Prostate|June 21, 2011
Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progressionDaniel Keizman, Peng Huang, Michael A Carducci, et al.
Pageof 33